Overview

Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related Cancers

Status:
Withdrawn
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
Non-randomized, open-label, multi-center, phase I/II, dose-escalation study of the combination of carboplatin, eribulin, and E7449.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio
Treatments:
Carboplatin
Poly(ADP-ribose) Polymerase Inhibitors